A pharmacy shall: Document and perform routine testing as required by USP 797 Standards for the appropriate risk levels of sterile compounded preparations; and Report to the Board within 5 calendar days: Adverse events that have been discovered including corrective actions taken or proposed; Deficiencies related to the sterile compounding process; Disciplinary actions in other states or by other state agencies; Changes in accreditation status; Disciplinary actions taken against a pharmacist who is an owner, operator, or employee of the pharmacy; and Disciplinary actions taken against any other known permit, or any other authorization, held by the pharmacy permit holder.